Oncotelic Therapeutics subsidiary Sapu Nano to present its Deciparticle nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026, seeking partnershipsOncotelic Therapeutics subsidiary Sapu Nano to present its Deciparticle nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026, seeking partnerships

Oncotelic’s Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO-Europe Spring 2026

2026/03/24 21:35
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The presentation will highlight the company’s next-generation drug delivery technology designed to improve therapeutic outcomes in oncology.

The company will showcase two lead candidates during the event. Sapu003 (Everolimus for Injection) is currently in Phase 1 clinical trials, while Sapu006 (Docetaxel for Injection) is entering Phase 1 studies. These developments represent significant steps in advancing nanomedicine applications for cancer treatment.

Oncotelic’s participation in BIO-Europe Spring 2026 comes as the company seeks strategic partnerships to advance development and commercialization of its technologies. The event serves as a platform for biotechnology companies to connect with potential partners and investors in the life sciences sector.

The company’s focus on improving drug delivery through nanotechnology has implications for enhancing therapeutic index and unlocking new clinical potential for established cancer treatments. This approach could potentially address limitations in current drug delivery methods and improve patient outcomes in oncology.

For investors seeking additional information about Oncotelic Therapeutics, the company maintains a newsroom at https://ibn.fm/OTLC where updates are regularly posted. The full press release announcing the BIO-Europe Spring 2026 presentation is available at https://ibn.fm/Slq47.

The presentation at BIO-Europe Spring 2026 represents an important opportunity for Oncotelic to demonstrate the potential of its Deciparticle platform to the international biotechnology community. As the company advances its clinical pipeline, this visibility could facilitate partnerships necessary for further development and eventual commercialization of its nanomedicine technologies.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic’s Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO-Europe Spring 2026.

The post Oncotelic’s Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO-Europe Spring 2026 appeared first on citybuzz.

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0.01645
$0.01645$0.01645
-2.08%
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Brothers’ American Bitcoin Hits BTC Milestone as Stock Falls to Lowest Price Since IPO

Trump Brothers’ American Bitcoin Hits BTC Milestone as Stock Falls to Lowest Price Since IPO

The post Trump Brothers’ American Bitcoin Hits BTC Milestone as Stock Falls to Lowest Price Since IPO appeared on BitcoinEthereumNews.com. In brief American Bitcoin
Share
BitcoinEthereumNews2026/03/31 01:01
What the Ethereum Economic Zone (EEZ) Means for ETH’s Future

What the Ethereum Economic Zone (EEZ) Means for ETH’s Future

The Ethereum Economic Zone (EEZ) is a new framework backed by the Ethereum Foundation, Gnosis, and Zisk that aims to address one of Ethereum’s biggest structural
Share
Ethnews2026/03/31 01:12
USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

A heated contest for control over a new dollar-pegged token has set the stage for what analysts say could define the next phase of the stablecoin industry. According to Bloomberg, a bidding war unfolded on Hyperliquid, one of crypto’s fastest-growing trading platforms, with the prize being the right to issue USDH, its native stablecoin. The competition drew some of the sector’s most prominent names, including Paxos, Sky, and Ethena, who later withdrew their bid, alongside the lesser-known Native Markets, a startup backed by Stripe stablecoin subsidiary Bridge. Hyperliquid Stablecoin Race Shows Branding and Partnerships Matter as Much as Tech Over the weekend, Hyperliquid’s validators, the contributors who secure the network and vote on key decisions, awarded the USDH contract to Native Markets over the weekend. Despite its relatively new status, the firm’s connection with Stripe helped it outpace more established rivals. Stablecoins underpin decentralized finance by providing a dollar-backed medium for collateral, settlement, and payments across applications. What began as a grassroots, community-led sector has evolved into a battleground for institutions and payment companies seeking revenue from interest on reserves. Circle, for example, shares proceeds from its USDC with Coinbase under a partnership designed to stabilize earnings during market swings. The Hyperliquid contest offered a rare glimpse into just how intense competition has become. Paxos pledged to take no revenue until USDH surpassed $1 billion in circulation. Agora offered to share 100% of net revenue with Hyperliquid, while Ethena put forward 95%. All were outbid by Native Markets, whose ties to Stripe’s $1.1 billion acquisition of Bridge and subsequent rollout of the Tempo blockchain positioned it as a strong contender. “Every stablecoin issuer is extremely desperate for supply,” said Zaheer Ebtikar, co-founder of Split Capital. “They are willing to publicly announce how much they are willing to offer. It just shows it’s a very tough business for stablecoin issuers.” While USDC remains dominant on Hyperliquid with more than $5.6 billion in deposits, the arrival of USDH could shift flows and revenue dynamics. Paxos co-founder Bhau Kotecha said the firm sees the exchange’s growth as an important opportunity, while Agora’s co-founder Nick van Eck warned that awarding the contract to a vertically integrated issuer risked undermining decentralization. Regulatory positioning also factored into the debate. Paxos operates under a New York trust charter and is seeking a federal license, while Bridge holds money transmitter approvals in 30 states. Native Markets, in a blog post, cited regulatory flexibility and deployment speed as reasons for its selection. Hyperliquid said the strong engagement from its community validated the process. Circle CEO Jeremy Allaire dismissed concerns over USDC’s status, noting on X that competition benefits the ecosystem. Analysts suggested that fears of centralization may be exaggerated, noting that Hyperliquid is likely to remain neutral and support multiple stablecoins. Still, the contest over USDH highlighted a new reality for stablecoins: branding, partnerships, and business strategy are becoming as decisive as technology. Native Markets Secures USDH Stablecoin Mandate on Hyperliquid Hyperliquid has concluded its governance vote for the USDH stablecoin, awarding the mandate to Native Markets after a closely watched process that drew weeks of community debate and rival proposals. USDH, described by Hyperliquid as a “Hyperliquid-first, compliant, and natively minted” dollar-backed token, is intended to reduce the platform’s dependence on USDC and strengthen its spot markets. Validators on the decentralized exchange voted in favor of Native Markets, a relatively new player backed by Stripe’s Bridge subsidiary, over established contenders including Paxos and Ethena. The outcome followed a string of proposals offering aggressive revenue-sharing terms to win validator support, underscoring the scale of incentives attached to controlling USDH. Hyperliquid’s exchange has become a critical hub for stablecoin liquidity, with $5.7 billion in USDC, around 8% of its total supply, currently held on the network. At prevailing treasury yields, that translates to an estimated $200 million to $220 million in annual revenue for Circle, underlining why a native alternative could be transformative. Hyperliquid’s validators, who secure the network and vote on key decisions, selected Native Markets following an on-chain governance process that concluded September 15. Native Markets has laid out a phased rollout for USDH, beginning with capped minting and redemption trials before expanding into spot markets. Its reserves will be managed in cash and treasuries by BlackRock, with on-chain tokenization through Superstate and Bridge. Yield from those reserves will be split between Hyperliquid’s Assistance Fund and ecosystem development. The launch of USDH comes as Hyperliquid records record profits from perpetual futures trading, with $106 million in revenue in August alone, and prepares to slash spot trading fees by 80% to bolster liquidity. Analysts say the move positions Hyperliquid to capture more of the stablecoin economics internally, marking a significant step in its bid to rival the largest players in decentralized finance
Share
CryptoNews2025/09/18 00:48